Advertisement

Agents and Actions

, Volume 27, Issue 3–4, pp 335–337 | Cite as

Inhibition of autoimmune disease and the generation of suppressor cells by spirogermanium: A biological profile similar to total lymphoid irradiation

  • A. M. Badger
  • C. K. Mirbelli
  • B. A. Swift
  • M. J. DiMartino
Animal Models

Abstract

Oral administration of spirogermanium (Sg), inhibits the development of immune-mediated hindpaw inflammation in the rat model of adjuvant arthritis (AA) and DTH responses to PPD (30 mg/kg/day). A similar dosing protocol inhibits hindleg paralysis in experimental autoimmune encephalomyelitis (EAE). The spleens of these animals and those of normal rats contain radiation resistant (2000 R) non-specific suppressor cells (SC) which bear some similarity to those generated following total lymphoid irridiation (TLI). These cells do not appear to be mature T cells, they are partially adherent to plastic, sephadex G10 and nylon wool, insensitive to indomethacin and are enriched in a 1.07 g/ml fraction of a Percoll density gradient.

Keywords

Nylon Oral Administration Indomethacin Density Gradient Experimental Autoimmune Encephalomyelitis 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. [1]
    L. Rice, J. W. Wheeler and C. F. Gerschickter,Spirans XXII. Synthesis of 4,4-dialkyl-4-germacyclohexanome and 8,8-dialkyl-8-germaspirol[4.5]decanes. J. Heterocyclic Chem.11, 1401–1406 (1974).Google Scholar
  2. [2]
    M. Slavik, L. Elias, J. Mrema and J. H. Saiers,Laboratory and clinical studies of spirogermanium, a novel heterocyclic anticancer drug. Drugs Exp. Clin. Res.8, 379–385 (1982).Google Scholar
  3. [3]
    Badger, A. M., C. K. Mirabelli and M. J. DiMartino,Generation of suppressor cells in normal rats by treatment with Spirogermanium, a novel heterocyclic anticancer drug. Immunopharmacology10, 201–207 (1985).Google Scholar
  4. [4]
    M. J. DiMartino, J. C. Lee, A. M. Badger, K. A. Muirhead, C. K. Mirabelli and N. Hanna,Antiarthritic and immunoregulatory activity of Spirogermanium. J. Pharm. Exp. Ther.236, 103–110 (1986).Google Scholar
  5. [5]
    A. M. Badger, M. J. DiMartino, T. C. Schmitt, B. A. Swift and C. K. Mirabelli,Suppressor cell induction by the anticancer drug spirogermanium. Int. J. Immunopharm.9, 621–630 (1987).Google Scholar
  6. [6]
    A. M. Badger, M. J. DiMartino, B. A. Swift and C. K. Mirabelli,Immunomodulatory activity and non-specific suppressor cell generation by spirogermanium in murine and rat models of cell-mediated immunity. Immunopharm.16, 33–43 (1988).Google Scholar
  7. [7]
    H. J. Sacks, V. Braunstein and C. F. Brosnan,Preliminary study on the suppression of experimental autoimmune encephalomyelitis in the Lewis rat with spirogermanium. J. Neuropathol. Exp. Neurol.46, 250–261 (1987).Google Scholar
  8. [8]
    S. Strober,Natural suppressor (NS) cells, neonatal tolerance, and total lymphoid irradiation: exploring obscure relationships. Annu. Rev. Immunol.2, 219–237 (1984).Google Scholar

Copyright information

© Birkhäuser Verlag 1989

Authors and Affiliations

  • A. M. Badger
    • 1
  • C. K. Mirbelli
    • 1
  • B. A. Swift
    • 1
  • M. J. DiMartino
    • 1
  1. 1.Smith Kline and French LaboratoriesKing of PrussiaUSA

Personalised recommendations